Theralase(R) Granted Canadian Cancer Vaccine Patent.

Theralase Technologies receives a patent for a cancer vaccine from the Canadian Intellectual Property Office. The vaccine, designed for specific cancer treatment, is set to undergo Phase II registration clinical study for bladder cancer in 2026 and a Phase Ib study for brain and lung cancer in 2024, pending toxicology results. The patent enables exploration of treatment for "liquid cancers" like leukemia, lymphoma, and myeloma.

April 05, 2024
4 Articles